EMEA-003546-PIP01-23 - paediatric investigation plan
zongertinib
PIPHuman
Key facts
- Active Substance
- zongertinib
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0108/2024
- PIP number
- EMEA-003546-PIP01-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of non-small cell lung cancer
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com
Tel. +49 (0)6132 77 8271
- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date